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Anemia represents an almost obligatory complication in patients
with chronic kidney disease (CKD) and, if ineffectively treated, is as-
sociated with increased cardiovascular (CV) mortality, a reduced
quality of life and the well know clinical consequences secondary to the
need of an exceedingly high number of iron infusions and red blood cell
(RBC) transfusions, which have been the only available therapy until
the end of 1980s [1,2].
Three decades ago, the introduction of recombinant erythropoietin
(rEPO) in the pharmaceutical market represented a great breakthrough
in the field of CKD treatment, greatly improving the effectiveness of the
control of anemia in CKD patients [3].
However, the results of three large interventional trials [4–6], al-
though confirming the effectiveness of rEPO in improving the control of
anemia in CKD and the reduced need for RBC transfusions, have raised
safety concerns due to the observation of an increased rate of CV events
and stroke, particularly in the case when trying to reach Hb levels close
to normality.
Furthermore, the correction of CKD anemia with rEPO is often
partial, with far from rare cases of true resistance to its action. In ad-
dition, rEPO treatment frequently leads to an increased need for iron
administration, with the clinical consequences caused by iron overload.
At the same time, nephrologists gained more and more awareness
that, though the reduced production of erythropoietin by the failing
kidneys plays a primary role in causing the anemia of CKD patients,
many other additional factors can actually contribute to anemia de-
velopment. Among them, the role of the functional iron deficiency
(FID), mainly secondary to the increased levels of hepcidin, an acute-
phase reactant protein, responsible for a reduced bioavailability of iron
(reduction of iron intestinal absorption and of its release from cellular
stores) gained a more and more relevant weight.
On this background, in the search for new drugs which could satisfy
the unmet needs of rEPO-based therapy, the emergent role of the small-
molecule inhibitors of prolyl hydroxylase domain (PHD) dioxygenases
has recently gained particular attention due to some promising pecu-
liarities.
The PHD proteins are a group of enzymes which, in the presence of
normoxic conditions and in cooperation with the Von Hippel Lindau
protein (pVHL), inactivate the oxygen-sensitive subunits of hypoxia-
inducible factor (HIF), namely HIF-2α and HIF-1α, by an ubiquitin-
proteasome mediated process [7,8]. Hypoxia strongly inhibits PHD
dioxygenase activity, stabilizing the HIFα molecules which, after di-
merizing with the constitutively expressed HIFβ, behave as transcrip-
tion factors (TFs) activating a number of target genes, among which
EPO gene and many genes involved in iron metabolism. So, the major
final effects of PHD inhibition and HIF stabilization are the increased
production of EPO, the increased iron bioavailability (mediated also by
the reduction of hepcidin, an inflammation related protein, which in-
hibits the release of iron from macrophages and the intestinal iron
absorption), and the direct bone marrow stem cell stimulation.
For these reasons, a number of compounds with inhibitory action on
PHD dioxygenases have now become object of intense clinical in-
vestigation [8]. Among these products, Roxadustat (FG 4592), an orally
active compound, with a half-life around 12–15 h, has been demon-
strated by some phase-II trials [9–11] to be effective, when given thrice
weekly, in the correction of anemia in CKD patients, either those on HD
treatment or those not on HD treatment. Based on these results, Rox-
adustat has been the first PHD dioxygenase inhibitor which achieved a
formal approval for clinical use, at the present time limited to the
treatment of anemia in hemodialysis (HD) and peritoneal dialysis (PD)
patients in China.
Very recently, the results of two phase-III RCTs which evaluated the
efficacy and safety of Roxadustat, used for correcting anemia in dialysis
[12] and in CKD stage 3–5 not on dialysis [13] patients, respectively,
have been reported in two papers published in the same issue of the
New England Journal of Medicine (N Engl J Med. 2019 Jul 24).
Both studies confirmed the efficacy of Roxadustat in the achieve-
ment of anemia correction which was not inferior to the correction
observed with rEPO (epoietin alfa) in CKD patients on HD and superior
to anemia control that was even worsened in CKD patients not on HD
treated with placebo. Furthermore, Roxadustat better preserved iron
balance, evaluated as the transferrin saturation levels and the need for
iron infusions, as compared to rEPO and even more to placebo.
In addition to these expected positive effects, both studies demon-
strated that Roxadustat significantly reduces the levels of both total
cholesterol and hepcidin, in comparison with either the rEPO and
placebo treated patients. Since both high hepcidin and cholesterol le-
vels are considered two among the main drivers of the increased in-
flammatory status and hence of the exceedingly high CV morbidity and
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mortality rate in CKD patients, these results could suggest an additional
beneficial effect in the use of Roxadustat and possibly of all the other
compounds of this new class of drugs in the clinical set of CKD patients.
On the other hand, in both trials Roxadustat was shown to induce an
increase in serum potassium levels, which might represent a critical
limitation in the use of this drug, in particular in CKD patients not as yet
on HD, who are often treated with other drugs which often induced
hyperkalemia (e.g. ace-inhibitors, angiotensin receptor blockers, anti-
aldosterone drugs).
Other undesired effects of Roxadustat, reported in these two clinical
trials, were the increased incidence of upper respiratory tract infections
(URTI) in CKD patients on HD [12] and increased occurrence of me-
tabolic acidosis (MA) in CKD patients not on HD [13]. The induction or
worsening of MA represents a concern in the use of this drug in patients
with CKD patients, given the recognized role of this metabolic altera-
tion in CKD progression. At the same time, given the increasing age of
CKD population and the increased susceptibility of older CKD patients
to infections, if confirmed in larger study also this observed higher
incidence of URTI might be reason of concern.
Overall, while these two RCTs might represent a potential first step
towards a radical shift of the therapeutic approach to anemia in CKD,
there are some critical limitation and consequently as yet unanswered
questions which deserve attention.
First, these studies included relatively small number of patients with
an unequal distribution of the enrolled subjects in the treatment and
comparator groups (2:1). We need larger studies, possibly based on a
1:1 enrollment design, to achieve more robust and informative evi-
dence.
Second, the enrolled patients were all of Chinese ethnicity: future
studies should enroll more patients from different Countries, to exclude
that some ethnic specificities can have affected some of the positive or
of the negative results.
Third, these trials do not face one of the most critical open ques-
tions: could be Roxadustat able to achieve a full correction of CKD
anemia without any major adverse effect, at variance with what ob-
served with rEPO? This is a key point for assessing whether CKD pa-
tients can really benefit or not by a complete correction of the he-
moglobin levels.
Fourth, the short duration of these two studies do not allow to draw
any definitive conclusion on the efficacy and, more important, on the
safety in the use of this new drug in the long run. This point is of
particular relevance at the light of the large series of either positive or
negative off-target effects which have been reported in small clinical
and/or experimental studies (Table 1) with the use of this new class of
drugs.
A potential further point to be explored is the possible reduction of
the adherence to the treatment with an oral drug in patients who are
usually burdened by a huge number of pills as compared with a therapy
which, at least in dialysis, is directly managed by the health workers.
Finally, the cost-effectiveness of these new drugs in comparison
with the already available therapeutic tools need to be explored, also
considering the considerable reduction in the costs of the therapy of
anemia in CKD after the introduction in the market of biosimilar rEPOs.
In conclusion, although Roxadustat can represent an innovative and
promising opportunity for the cure of anemia in CKD patients, we still
need more evidence from larger and longer studies, preferably per-
formed in different ethnic groups.
It would be desirable that these additional studies will not limit
themselves to report on the secondary endpoints associated with the
anemia control, but they also give information on many additional
clinical and metabolic parameter, which can be potentially affected by
the purported off-target effects: these studies will reassure the medical
community on the safety issues linked to potential long-term effects of
these new promising class of drugs.
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